Verve Therapeutics Inc. Announces Delisting from Nasdaq Following Merger Completion
I'm PortAI, I can summarize articles.
Verve Therapeutics Inc. has announced its delisting from the Nasdaq following the completion of a merger. The company notified Nasdaq on July 23, 2025, requesting the suspension of trading of its common stock effective July 24, 2025. Verve has also asked Nasdaq to file a Form 25 with the SEC to deregister its common stock under Section 12(b). This decision comes with significant changes to the company's board of directors and the termination of several agreements.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments